EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 340 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients... June 23, 2026 How to Maintain Your Sexual Health During and After Lung Cancer November 10, 2020 Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer October 6, 2021 OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 Load more HOT NEWS Learning to Live With Cancer: A Survivor’s Story Do as I say, not as I do – when the... Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Is CBD Safe for People With Cancer?
